Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients

Nai Shun Yao, Yi Ying Wu, Anthony J. Janckila, Chih Hung Ku, An Tai Hsieh, Ching Liang Ho, Su Huei Lee, Tsu Yi Chao

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Diagnosis and follow-up of bone metastasis (BMet) in non-small cell lung cancer (NSCLC) patients usually rely on symptoms and image studies. A serum marker of bone resorption may improve the quality of treatment in such patients. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker for osteoclasts and we proposed it can be used as a marker of BMet in NSCLC patients. Methods: In November 2002 till August 2008 serum samples were obtained from 141 newly diagnosed stage IIIA, IIIB or IV NSCLC patients and 41 normal subjects. All patients received baseline bone scintinography examination and evaluation of clinical symptoms as a standard of BMet diagnosis. Patients were divided into 2 groups by having BMet (Group I, n= 72) or not (Group II, n= 69). An in-house immunoassay using a TRACP-specific monoclonal antibody, 14G6, was used to measure the serum TRACP5b activity at pH 6.1. Results: The mean serum TRACP5b activities of Group I, Group II and normal subjects were 3.50. ±. 2.23. U/l, 2.09. ±. 0.72. U/l and 2.33. ±. 0.52. U/l, respectively. After adjusting for age, stage, gender, and histology in a generalized linear model, Group I has significantly higher TRACP5b activity than Group II (p

Original languageEnglish
Pages (from-to)181-185
Number of pages5
JournalClinica Chimica Acta
Volume412
Issue number1-2
DOIs
Publication statusPublished - Jan 14 2011

Fingerprint

Biomarkers
Acid Phosphatase
Non-Small Cell Lung Carcinoma
Bone
Cells
Neoplasm Metastasis
Bone and Bones
Serum
Histology
Symptom Assessment
Osteoclasts
Bone Resorption
Immunoassay
Tartrate-Resistant Acid Phosphatase
tartaric acid
Linear Models
Monoclonal Antibodies

Keywords

  • Bone metastasis
  • Lung cancer
  • Osteoclast
  • Tartrate-resistant acid phosphatase 5b

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. / Yao, Nai Shun; Wu, Yi Ying; Janckila, Anthony J.; Ku, Chih Hung; Hsieh, An Tai; Ho, Ching Liang; Lee, Su Huei; Chao, Tsu Yi.

In: Clinica Chimica Acta, Vol. 412, No. 1-2, 14.01.2011, p. 181-185.

Research output: Contribution to journalArticle

Yao, Nai Shun ; Wu, Yi Ying ; Janckila, Anthony J. ; Ku, Chih Hung ; Hsieh, An Tai ; Ho, Ching Liang ; Lee, Su Huei ; Chao, Tsu Yi. / Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. In: Clinica Chimica Acta. 2011 ; Vol. 412, No. 1-2. pp. 181-185.
@article{2fc0a988faec42988bec5e7d58a2df67,
title = "Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients",
abstract = "Background: Diagnosis and follow-up of bone metastasis (BMet) in non-small cell lung cancer (NSCLC) patients usually rely on symptoms and image studies. A serum marker of bone resorption may improve the quality of treatment in such patients. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker for osteoclasts and we proposed it can be used as a marker of BMet in NSCLC patients. Methods: In November 2002 till August 2008 serum samples were obtained from 141 newly diagnosed stage IIIA, IIIB or IV NSCLC patients and 41 normal subjects. All patients received baseline bone scintinography examination and evaluation of clinical symptoms as a standard of BMet diagnosis. Patients were divided into 2 groups by having BMet (Group I, n= 72) or not (Group II, n= 69). An in-house immunoassay using a TRACP-specific monoclonal antibody, 14G6, was used to measure the serum TRACP5b activity at pH 6.1. Results: The mean serum TRACP5b activities of Group I, Group II and normal subjects were 3.50. ±. 2.23. U/l, 2.09. ±. 0.72. U/l and 2.33. ±. 0.52. U/l, respectively. After adjusting for age, stage, gender, and histology in a generalized linear model, Group I has significantly higher TRACP5b activity than Group II (p",
keywords = "Bone metastasis, Lung cancer, Osteoclast, Tartrate-resistant acid phosphatase 5b",
author = "Yao, {Nai Shun} and Wu, {Yi Ying} and Janckila, {Anthony J.} and Ku, {Chih Hung} and Hsieh, {An Tai} and Ho, {Ching Liang} and Lee, {Su Huei} and Chao, {Tsu Yi}",
year = "2011",
month = "1",
day = "14",
doi = "10.1016/j.cca.2010.09.038",
language = "English",
volume = "412",
pages = "181--185",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients

AU - Yao, Nai Shun

AU - Wu, Yi Ying

AU - Janckila, Anthony J.

AU - Ku, Chih Hung

AU - Hsieh, An Tai

AU - Ho, Ching Liang

AU - Lee, Su Huei

AU - Chao, Tsu Yi

PY - 2011/1/14

Y1 - 2011/1/14

N2 - Background: Diagnosis and follow-up of bone metastasis (BMet) in non-small cell lung cancer (NSCLC) patients usually rely on symptoms and image studies. A serum marker of bone resorption may improve the quality of treatment in such patients. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker for osteoclasts and we proposed it can be used as a marker of BMet in NSCLC patients. Methods: In November 2002 till August 2008 serum samples were obtained from 141 newly diagnosed stage IIIA, IIIB or IV NSCLC patients and 41 normal subjects. All patients received baseline bone scintinography examination and evaluation of clinical symptoms as a standard of BMet diagnosis. Patients were divided into 2 groups by having BMet (Group I, n= 72) or not (Group II, n= 69). An in-house immunoassay using a TRACP-specific monoclonal antibody, 14G6, was used to measure the serum TRACP5b activity at pH 6.1. Results: The mean serum TRACP5b activities of Group I, Group II and normal subjects were 3.50. ±. 2.23. U/l, 2.09. ±. 0.72. U/l and 2.33. ±. 0.52. U/l, respectively. After adjusting for age, stage, gender, and histology in a generalized linear model, Group I has significantly higher TRACP5b activity than Group II (p

AB - Background: Diagnosis and follow-up of bone metastasis (BMet) in non-small cell lung cancer (NSCLC) patients usually rely on symptoms and image studies. A serum marker of bone resorption may improve the quality of treatment in such patients. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker for osteoclasts and we proposed it can be used as a marker of BMet in NSCLC patients. Methods: In November 2002 till August 2008 serum samples were obtained from 141 newly diagnosed stage IIIA, IIIB or IV NSCLC patients and 41 normal subjects. All patients received baseline bone scintinography examination and evaluation of clinical symptoms as a standard of BMet diagnosis. Patients were divided into 2 groups by having BMet (Group I, n= 72) or not (Group II, n= 69). An in-house immunoassay using a TRACP-specific monoclonal antibody, 14G6, was used to measure the serum TRACP5b activity at pH 6.1. Results: The mean serum TRACP5b activities of Group I, Group II and normal subjects were 3.50. ±. 2.23. U/l, 2.09. ±. 0.72. U/l and 2.33. ±. 0.52. U/l, respectively. After adjusting for age, stage, gender, and histology in a generalized linear model, Group I has significantly higher TRACP5b activity than Group II (p

KW - Bone metastasis

KW - Lung cancer

KW - Osteoclast

KW - Tartrate-resistant acid phosphatase 5b

UR - http://www.scopus.com/inward/record.url?scp=78650512206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650512206&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2010.09.038

DO - 10.1016/j.cca.2010.09.038

M3 - Article

C2 - 20932965

AN - SCOPUS:78650512206

VL - 412

SP - 181

EP - 185

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -